Issue Highlights

Abstract

IUBMB LifeVolume 72, Issue 8 p. 1545-1545 ISSUE HIGHLIGHTSFree Access Issue Highlights First published: 22 July 2020 https://doi.org/10.1002/iub.2360AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat 1649 Cytotoxic T lymphocytes exert potent antitumor activity by recognizing the antigen peptide and major histocompatibility complex (MHC) on cancer cells through the T-cell receptor (TCR). Adoptive T-cell therapy (ACT) is a treatment method in which tumor antigen-specific T cells from a cancer patient are activated and expanded in vitro, and then transplanted back into the cancer patient. One of the limiting factors of ACT is that the administered T cells are rendered dysfunctional due to the immunosuppressive tumor microenvironment. We attempted to inhibit interaction between programmed death-1 (PD-1) and its ligand (PD-L1) by genetically modifying T cell medicine to express the anti-PD-L1 molecules. Anti-PD-L1 molecule expression was functional in avoiding T-cell dysfunction by PD-L1/PD-1 signaling. Our concept of anti-PD-L1 molecule-expressing T-cell medicine is thus expected to improve the efficacy of ACT. REFERENCES 1Kento Fujiwara, Kazuki Shigematsu, Masashi Tachibana, Naoki Okada. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability. IUBMB Life. 2020, 72, 1649– 1658. Volume72, Issue8August 2020Pages 1545-1545 ReferencesRelatedInformation